Coya Therapeutics
0 followers
‌
Coya is developing disruptive, first in class, autologous regulatory T-cell (Treg) and allogeneic exosome therapies - leveraging the seminal discoveries from the laboratory of Stanley Appel M.D., in which dysfunctional Tregs modulate neurodegenerative and autoimmune diseases.
Industries
Headquarters
Employees
Links
Org chart
Howard Berman
CEO & Chairman
Howard Berman
Collapse
Adrian Hepner
Strategic & Clinical Advisor
David S. Snyder
CFO & COO
Gregory MacMichael
Chief Technical Officer
Aaron Thome
Head, Neuroinflammation Platform
David Beers
Head, Biomarker Program
Arun Swaminathan
Chief Executive Officer/member Of The Board
Fred Grossman D.O., FAPA
President and Chief Medical Officer
